Introduction
============

The cornea, the anterior structure of the eye, is a convex transparent barrier. It serves to maintain the intact structure of the eye and focus a clear and minimally deviated penetration of light onto the retina. It consists of five anatomically separate layers: epithelium; Bowmen's layer; stroma; Descement's membrane; and endothelium. The stroma accounts for 90% of the corneal thickness. It is composed mainly of type 1 collagen fibrils with types III, V, and VI also found. These are woven into equidistant lamellae, interspersed with keratocytes. These are charged with stromal maintenance and wound healing ([@b37-co-2-863]).

Corneal ectasia represents a group of disorders characterized by inherent corneal weakness and instability leading to protrusion, astigmatism, loss of visual acuity, and potentially even perforation ([@b15-co-2-863]). This entity comprises of both primary and secondary or iatrogenic conditions, all leading to similar manifestations of loss of corneal stability. Of the congenital disorders, keratoconus represents the primary cause, affecting up to one in 2000 people ([@b26-co-2-863]). This congenital, noninflammatory, usually bilateral disease manifests as a progressing stromal instability, leading to a reduction in corneal rigidity ([@b1-co-2-863]) and may affect visual acuity to such an extent as to require penetrating keratoplasy in up to 20% of patients ([@b25-co-2-863]). Treatment options include conservative approaches, aimed at maintaining visual acuity, such as rigid contact lenses placed to straighten corneal aberrations ([@b7-co-2-863]). Alternatively, more invasive methods are applied using intrastromal corneal implants ([@b6-co-2-863]), performing anterior lamellar keratoplasty, and penetrating keratoplasty in extreme cases ([@b25-co-2-863]; [@b35-co-2-863]). However, these therapies only address the refractive consequences of the disease and not the underlying pathology, namely a stromal instability stemming from collagen abnormalities ([@b26-co-2-863]), and with the exception of corneal transplantation do not halt the progression of the disease.

Collagen cross-linking is a new approach that directly targets these stromal imbalances. By using ultraviolet (UV) irradiation and a photomediator, new covalent cross links are induced between collagen fibrils and corneal rigidity improved ([@b38-co-2-863]). Cross-linking is a well established method used in polymer industries for the stabilization of tissues. Chemical cross-linking with glutaraldehyde is used in the preparation of prosthetic heart valves ([@b11-co-2-863]), papraformaldehyde is used for tissue hardening in pathology ([@b22-co-2-863]) and UV cross-linking is used to harden dentistry fillings ([@b4-co-2-863]). Furthermore, studies have shown that keratoconus is an uncommon phenomenon among diabetic patients, as well as progression of the disease at an older age. This possibly reflects collagen cross-linking induced by advanced glycation endproducts ([@b2-co-2-863]; [@b29-co-2-863]; [@b16-co-2-863]), or following age-related cross-linking ([@b27-co-2-863]; [@b19-co-2-863]; [@b5-co-2-863]).

Method
======

Inducing cross links between neighboring collagen fibers is achieved by combining the photosensitizer riboflavin with an initiating UVA beam. Exposing riboflavin to UVA light promotes its photomediator properties and extends the effects of the irradiation to the surrounding tissue. Following exposure, riboflavin is excited into a triplet state thereby generating reactive oxygen species; singlet oxygen and superoxide anions. These then act to induce the formation of new covalent bonds between the amino acids of neighboring collagen fibers ([@b29-co-2-863]). The wavelength of 370 nm is used to achieve maximal absorption by the riboflavin, while remaining below harmful DNA and retinal radiation levels ([@b31-co-2-863]).

The treatment is conducted following local anesthesia of the eye. An abrasion of a central corneal circle is created by mechanical removal of the epithelium for better riboflavin diffusion into the stroma. This is made at a size of between 5--9 mm according to the desired treatment area ([@b3-co-2-863]; [@b9-co-2-863]; [@b12-co-2-863]). A 0.1% riboflavin solution in 20% dextran is applied manually every 2--5 minutes, starting 5 minutes before UVA exposure to allow stromal saturatuion. The irradiation is performed from a distance of 1 cm for 30 minutes. A UVA diode at a wave length of 365--370 nm is used to deliver an irradiance of 3 mW/cm^2^ (a total dose of 5.4 J/cm^2^ of the cornea) ([@b40-co-2-863]; [@b28-co-2-863]). Repeated applications of riboflavin and topical anesthesia to the cornea are performed every 5 minutes. Corneal temperature during the procedure is constant and does not cause thermal damage ([@b23-co-2-863]). It should be noted that alternative protocols have been reported using irradiances distances of up to 10 cm ([@b9-co-2-863]; [@b21-co-2-863]), riboflavin application up to 30 minutes before irradiation ([@b9-co-2-863]; [@b31-co-2-863]) and repeated applications of physiological salt solutions to maintain corneal moisture ([@b9-co-2-863]; [@b18-co-2-863]). Following the treatment a contact lens is fitted until re-epitalization and local antibiotics and steroids are applied for a duration of up to several weeks ([@b40-co-2-863]; [@b9-co-2-863]; [@b31-co-2-863]).

Discussion
==========

The efficacy and safety of this new, minimally invasive method for correcting corneal ectasia has been the focus of recent studies. Most work has focused around keratoconus patients, while more recent reports have been published on iatrogenic corneal ectasia as following laser-assisted in situ keratomileusis (LASIK) ([@b9-co-2-863]; [@b14-co-2-863]).

To examine the change in corneal rigidity stress-strain tests were conducted on porcine corneas. These tests showed that collagen cross-linking by glutaraldehyde, Karnovsky's solution, or riboflavin-UV irradiation increased the rigidity of the treated corneas compared with controls ([@b30-co-2-863]; [@b32-co-2-863]). The treated porcine corneas showed an average increase in rigidity of 71.9%, while stiffness of treated human corneas increased by a mean of 328.9% ([@b41-co-2-863]).

Although the treatment increased the mechanical strain of the cornea, its effect was not uniform through its entire depth. Stress-strain tests conducted on anterior and posterior corneal flaps showed a significant increase in corneal stiffness in the anterior 200 μm compared with the posterior 200 μm. The stiffness of the posterior treated sections showed no difference from that of untreated controls ([@b13-co-2-863]). Furthermore, histological sections of treated corneas revealed that the treatment effected the cornea up to a depth of 300 μm, creating a clinically visible demarcation line separating the anterior cross-linked stroma and the posterior unaffected cornea ([@b28-co-2-863]). This suggests that the UVA irradiation is lost across the cornea and does not penetrate its full depth, possibly due to a shielding effect of the photosensitizer riboflavin that absorbs up to 95% of the UVA radiation at the endothelium level ([@b31-co-2-863]). Thus, a constant depth of effect is achieved with no disturbance to underlying structures including the endothelium. This may also explain the difference in increased rigidity observed between human and porcine corneas. Whereas in human corneas over 50% of the corneal thickness was effected (central corneal thickness was measured as 550 ± 40 μm), under 40% of the porcine corneas was treated (central corneal thickness of 850 ± 70 μm) ([@b41-co-2-863]). Such cross-linked corneas also displayed increased resistance to collagen enzymatic ingestion ([@b34-co-2-863]) and thermal shrinkage ([@b33-co-2-863]), further indicating an increased stiffness.

To explore the cellular effects of this treatment, histological sections were obtained from both treated animal and human corneas. Measurements of anterior section collagen diameter of treated rabbit corneas showed an increase of 12.2% compared to controls. This was also significantly greater than an increase of 4.6%, noted in posterior sections ([@b43-co-2-863]). Such increased diameter may reflect a molecular spacing of the collagen, brought on by the oxidative induced links between fibers ([@b36-co-2-863]). Histological evaluation further revealed a delayed process of keratocyte apoptosis, peaking at 24 hours following treatment. The extent and depth of cell death were dose-dependent, reaching 300 μm at the clinically used surface irradiance of 3 mW/cm2 ([@b43-co-2-863]), and correlating to the affected zone according to the tensile studies. Such delayed type apoptosis was observed at all treated levels, even at the endothelial cell layer when treatment was directed at rabbit corneas under 400 μm thickness ([@b41-co-2-863]). Serial histological follow-up of treated rabbit corneas revealed that following such extensive apoptosis, a regeneration process is initiated, leading by 4--6 weeks to a repopulation of both stromal keratocyes and spacing out of endothelial cells ([@b39-co-2-863]). Confocal microscopy studies conducted on corneas of human keratoconus patients showed a depletion of keratocytes in the treated zone up to a depth of 350 μm, not affecting the endothelium ([@b21-co-2-863]). The numbers of keratocytes decreased during the first 2--3 months following treatment, when a repopulation by activated keratocytes took place, peaking at 6 months. In these patients, keratocyte depletion was accompanied by an increased corneal edema, which resolved with keratocyte repopulation.

Thus, these studies show that while collagen cross-linking induces cellular apoptosis in all treated layers, later regeneration processes result in repopulation and normal tissue histology. However, it should be noted that as endothelial cells do not regenerate, any damage to the endothelium is irreversible. In cases when the endothelium is affected, as is the concern in patients with corneas under 400 μm ([@b41-co-2-863]), the long term consequences of such irreversible damage remain unknown. As the treatment affects a known and constant range, damage to such deeper structures may be averted by maintaining a minimal corneal thickness before treatment.

To date, few studies have examined the effectiveness of collagen cross-linking in treating keratoconus and improving visual acuity. In a prospective study, [@b40-co-2-863], [@b42-co-2-863] performed collagen cross-linking on 22 moderate to severe keratoconus patients. Follow-up was for up to 4 years (3--47 months) and included visual acuity, corneal topography and endothelial cell counts. In 20 patients refractive follow-up was performed. In 19 patients, K readings did not progress and in 65% of cases an average regression of 2.0 diopters was noted. Best corrected visual acuity (BCVA) improved in 65% of cases by an average of 1.26 lines and the spherical equivalent refractive error by an average of 1.14 diopters. No significant change in endothelial cell density or other adverse reactions were noted. Although follow-up time among the different patients varied, this work was the first to show a significant improvement in the outcome of moderate and severe keratoconus patients following collagen cross-linking treatment. In a second study 10 patients were followed for 6 months after the procedure. In these cases BCVA improved by an average of 1.66 lines with a mean K readings reduction of 2.1 diopters. As in the former study, no changes were noted in endothelial cell counts or intraocular pressure ([@b3-co-2-863]). These first clinical studies provide evidence regarding the medium term benefit of this procedure and also indicate that no other corneal effects take place. Recently a case report has been published of a keratoconus patient, with a BCVA of 20/40, who underwent CCL in one eye ([@b12-co-2-863]). Twelve months later topography-guided photorefractive keratectomy (PRK) was performed on the same eye. He was followed for another 18 months and his final BCVA was 20/15, with no change to endothelial cell counts. Meanwhile, BCVA of his untreated eye regressed from 20/15 to 20/25.

Recent reports suggest this method may have potential uses also in non keratoconus corneal ectasia ([@b14-co-2-863]). [@b9-co-2-863] reported a series of 10 patients treated with collagen cross-linking following LASIK-induced keratectasia. Patients were followed for up to 25 months post-treatment. In all cases the progression of corneal ectasia was halted with an improvement in 5 patients of over 2 diopters in K readings. Furthermore, in 4 cases BCVA improved by more than 2 lines.

Though collagen cross-linking is a minimally invasive method, recent reports have indicated possible adverse effects. [@b20-co-2-863] have presented two cases of postoperative corneal haze among a cohort of 40 eyes of 39 keratoconus patients. Preoperative BCVA and keratometric readings as well as *in vivo* confocal examinations were performed on all patients. They report confocal findings which possibly reflect keratoconus. In two cases unchanging stromal haze appeared 2--3 months following the procedure and was resistant to topical steroid treatment. Repeated examination of the preoperative confocal studies of these patients revealed a reticular pattern of stromal microstriae that may imply advanced keratoconus. BCVA in these patients improved despite the haze. Although these confocal findings are not unequivocally due to keratoconus, the authors suggest them to be a relative contra-indication to performing the procedure. Additional case reports describe diffuse lamellar keratitis ([@b17-co-2-863]) and a reactivation of herpetic keratitis ([@b18-co-2-863]) following collagen cross-linking. In both cases prompt diagnosis and treatment resulted in a favorable resolution.

When judging the use of a treatment with the potential of causing damage to ocular structures one must consider its safety and possible harmful consequences. UV radiation is known to be harmful to the endothelium, lens, and retina ([@b24-co-2-863]; [@b8-co-2-863]). Using a wavelength of 360--370 nm with an accumulated irradiance of 5.4 J/cm^2^ ensures that the exposure of all these structures is below harmful levels ([@b31-co-2-863]). However, the occurrence of a nonhomogenous irradiation field may create localized hot spots of increased radiance with potential harmful consequences. Therefore, for clinical use, a uniformly emitting irradiance source is needed and must be continuously evaluated. Further protection is achieved by the presence of riboflavin in the cornea, which was shown to reach up to 400 μm after 30 minutes of application. This then provides an UV absorption coefficient that shields the more posterior structures including the endothelium ([@b31-co-2-863]). When treatment was conducted on corneas of less than 400 μm, apoptotic damage was noted in the endothelium ([@b41-co-2-863]). This issue may be of greater concern when treating patients following LASIK when the post-treatment effective corneal thickness may very well be under 400 μm ([@b9-co-2-863]). While the shielding effect and distance from the treated area ensure the lens and retina are exposed to radiation well below harmful levels, the endothelium is still exposed to radiance which is lower than harmful levels only by a factor of 2 (0.32 J/cm^2^) ([@b31-co-2-863]). Thus, any variance in the irradiation field or corneal thickness may lead to direct damage to this layer. To ensure that the conducted procedure is safe to all ocular structures it is paramount to maintain a homogenous irradiation field at a wavelength and irradiance below harmful levels, good stromal penetration of riboflavin and adequate corneal thickness. For a more detailed review of the safety considerations of collagen cross-linking see [@b31-co-2-863].

Our personal experience with collagen cross-linking includes 70 patients treated during the past 2 years. Most patients suffered from keratoconus (n = 68), 12 treated following the insertion of intra-stromal corneal rings. The remaining patients (n = 2) were treated for corneal ectasia following LASIK surgery. Our overall impression in these cases is of an improvement in K readings and BCVA, with no adverse events noted to date.

Conclusions
===========

Keratoconus, and other corneal ectasias, present us with a treatment challenge in the hope of halting their progression and possibly correcting any refractive and stability deterioration. Studies in both animal models and human patients indicate that collagen cross-linking results in an increase in corneal stiffness and improvement of visual acuity. Furthermore, although the method affects the cellular composition of irradiated structures no lasting effect is generally noted in corneal architecture. Collagen cross-linking provides us for the first time with a minimally invasive approach to addressing the underlying pathology in corneal ectasia, halting its progression, and possibly even improving visual acuity. While it may halt progression of corneal ectasia, collagen cross-linking does not in itself affect corneal curvature, and thus may require the use of other means, such as intrastromal corneal rings ([@b6-co-2-863]) or rigid contact lenses ([@b7-co-2-863]) to correct refractive errors ([@b35-co-2-863]). Though this method appears to offer an improvement to patients suffering from corneal ectasia, it must be noted that its safety and long-term effects have not been extensively studied. The turnover rate of collagen fibers in the cornea is several years ([@b10-co-2-863]) and it remains unclear whether the changes noted in corneal stability will last or whether its effects are limited. Furthermore, the effect of corneal thickness on endothelial and ocular damage remains a safety concern. Future studies are needed to explore these long-term effects as well as other aspects of ocular safety.
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